After a big run-up in its share price following better-than-expected earnings and guidance in November, Antares Pharma (NASDAQ: ATRS) shares are down 10% at 3:30 p.m. EDT on Thursday. The company didn't report any news, so today's drop could be a simple case of profit-taking following a nearly 40% gain since October 31.
The company reported it's first quarterly operating profit in history in November, thanks to nearly triple-digit revenue growth following the launch of Xyosted -- a weekly testosterone product -- and Teva Pharmaceutical's (NYSE: TEVA) launch of a generic alternative to Mylan's EpiPen.
IMAGE SOURCE: GETTY IMAGES.